ClinicalTrials.gg
Sign In
CompletedNCT01872897Updated Apr 29, 2025Results posted

Compound Sodium Alginate Double Action Chewable Tablets 4-hour Esophageal pH Study in GERD Patients

A Phase 3 interventional study of Sodium Alginate Double Action Chewable Tablets and Placebo in Gastroesophageal Reflux Disease, sponsored by Reckitt Benckiser Healthcare (UK) Limited. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-04-29.

Sponsored by Reckitt Benckiser Healthcare (UK) Limited (part of Reckitt) · Phase 3, Interventional, and Treatment

Phase
Phase 3
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This study is being conducted to assess the effectiveness of the Compound Sodium Alginate Double Action Chewable Tablets compared to placebo on acidic reflux events into the esophagus in patients diagnosed with Gastroesophageal Reflux Disease (GERD).

02

Conditions studied

  • Gastroesophageal Reflux Disease

Keywords

  • Gastroesophageal Reflux Disease
  • GERD
  • Acid reflux
  • Compound Sodium Alginate Double Action Chewable Tablet
  • Gaviscon Double Action Tablets
03

In context

Gastroesophageal Reflux

1,211 studies on the registry are indexed under Gastroesophageal Reflux; 202 are open to participants now.

This study's enrollment of 45 is below the median of 68 across 796 interventional studies indexed under Gastroesophageal Reflux.

Browse Gastroesophageal Reflux studies →

Lead sponsor

Reckitt Benckiser Healthcare (UK) Limited is the lead sponsor of 35 studies on the registry; none are open to participants now.

Browse Reckitt Benckiser Healthcare (UK) Limited studies →All Reckitt studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • meets the diagnostic criteria for GERD with a GERD history of frequent episodes of GERD-related symptoms during the last 2 months prior to study screening. The patient must also meet the following criteria:

    1. The only or main symptom is heartburn (burning feeling back of breast bone) and/or acid reflux. Symptoms persist or have occurred repeatedly for more than 2 months;
    2. As assessed by the Investigator at screening by questioning of the patient, the frequency of occurrence of heartburn is ≥ 3 days/week and the score of severity of heartburn in general is ≥ moderate within 3 weeks before screening

Exclusion criteria

Exclusion Criteria:

  • Patients who have a history of drug, solvent or alcohol abuse (weekly alcohol intake ≥ 140 g).
  • Patients who have suffered cardiac chest pain within the last year.
  • Patients who have suffered a recent, significant unexplained weight loss of more than 6 kg in the last 6 months.
  • Female patients of who, for the duration of the study, are either unwilling or unable to take adequate precautions or are unwilling to be sexually abstinent.
  • Pregnancy or lactating mother.
  • Patients with a history and/or symptom profile suggestive of the following: any other gastrointestinal (GI) disease, erosive GERD (Los Angeles [LA] classification grades C-D), Barrett's oesophagus, acute peptic ulcer and/or ulcer complications, Zollinger-Ellison syndrome, gastric carcinoma, pyloric stenosis, oesophageal or gastric surgery, intestinal obstruction, current pernicious anaemia, indication for H. pylori eradication therapy, known gastrointestinal bleeding (hematochezia or hematemesis) within the last 3 months, and severe diseases of other major body systems.
  • Patients who are observed at screening to have a hiatus hernia with a diameter which exceeds 3 cm.
  • Patients who have taken anti-cholinesterase drugs, traditional Chinese medicines for treating gastrointestinal disease, ulcerlmin or misoprostol preparations within 7 days prior to screening or throughout the study.
  • Patients who have taken PPIs during the 10 days prior to screening, prokinetics or H2 antagonists during the 5 days prior to screening or systemic glucocorticosteroids, non-steroidal anti-inflammatory drugs (except for low dose aspirin which can be given for cardioprotection) on more than 3 consecutive days or PPI-based triple or quadruple therapy for eradication of H. pylori during the last 28 days.
  • Patients taking or requiring to take macrolide antibiotics, such as erythromycin, azithromycin, from the day before screening.
  • Patients with difficulty in swallowing.
  • Patients with known hypophosphataemia, phenylketonuria or hypercalcaemia.
  • Patients with severe constipation, or history of intestinal obstruction.
  • In the opinion of the Investigator, patients with damaged heart or kidney function and patients who require a low sodium diet.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
45 participants (actual)

Study arms

  • Active comparator
    Sodium Alginate Double Action Chewable Tablets, then Placebo tablets

    4 Compound Sodium Alginate Double Action Chewable Tablets administered as a single dose, followed by 7 days of Compound Sodium Alginate Double Action Chewable Tablets (two tablets four times daily), then a single dose of 4 Placebo tablets

    Drug: Sodium Alginate Double Action Chewable Tablets

  • Placebo comparator
    Placebo tablets, then Sodium Alginate Double Action Chewable Tablets

    Single dose of 4 Placebo tablets, followed by 7 days of Compound Sodium Alginate Double Action Chewable Tablets (two tablets four times daily), then a single dose of 4 Compound Sodium Alginate Double Action Chewable Tablets

    Drug: Sodium Alginate Double Action Chewable Tablets · Drug: Placebo

Interventions

  • DrugSodium Alginate Double Action Chewable Tablets

    4 tablets as a single dose

    Also known as: Gaviscon Double Action Tablets

  • DrugPlacebo

    4 tablets as a single dose

06

What researchers measure

Primary outcomes

  1. Percentage of Time During the 4-hour Post-dosing Period With pH Below pH 4

    The primary efficacy endpoint will be the percentage of time during the 4-hour post-dosing period with pH below pH 4 for Compound Sodium Alginate Double Action Chewable Tablets versus matching placebo tablets

    Time frame: 0 to 4 hours post-dose

Secondary outcomes

  1. Percentage of Time During the 4-hour Post-dosing Period With pH Below pH 5

    Percentage of time during the 4-hour post-dosing period with pH below pH 5 for Compound Sodium Alginate Double Action Chewable Tablets versus matching placebo tablets

    Time frame: 0 to 4 hours post-dose

  2. Number of Occasions During the 4-hour Post-dosing Period When pH Falls Below pH 4

    Number of occasions during the 4-hour post-dosing period when pH falls below pH 4 for Compound Sodium Alginate Double Action Chewable Tablets versus matching placebo tablets

    Time frame: 0 to 4 hours post-dose

  3. Number of Occasions During the 4-hour Post-dosing Period When pH Falls Below pH 5

    Number of occasions during the 4-hour post-dosing period when pH falls below pH 5 for Compound Sodium Alginate Double Action Chewable Tablets versus matching placebo tablets

    Time frame: 0 to 4 hours post-dose

  4. Number of Reflux Episodes During the 4-hour Post-dosing Period With pH Below pH 4 for at Least 5 Minutes

    Number of reflux episodes during the 4-hour post-dosing period with pH below pH 4 for at least 5 minutes for Compound Sodium Alginate Double Action Chewable Tablets versus matching placebo tablets

    Time frame: 0 to 4 hours post-dose

  5. Percentage of Time During the First Hour Post-dosing With pH Below pH 4

    Percentage of time during the first hour post-dosing with pH below pH 4 for Compound Sodium Alginate Double Action Chewable Tablets versus matching placebo tablets

    Time frame: 0 to 1 hour post-dose

  6. Percentage of Time During the First Hour Post-dosing With pH Below pH 5

    Percentage of time during the first hour post-dosing with pH below pH 5 for Compound Sodium Alginate Double Action Chewable Tablets versus matching placebo tablets

    Time frame: 0 to 1 hour post-dose

  7. Number of Occasions During the First Hour Post-dosing When pH Falls Below pH 4

    Number of occasions during the first hour post-dosing when pH falls below pH 4 for Compound Sodium Alginate Double Action Chewable Tablets versus matching placebo tablets

    Time frame: 0 to 1 hour post-dose

  8. Number of Occasions During the First Hour Post-dosing When pH Falls Below pH 5

    Number of occasions during the first hour post-dosing when pH falls below pH 5 for Compound Sodium Alginate Double Action Chewable Tablets versus matching placebo tablets

    Time frame: 0 to 1 hour post-dose

  9. The Longest Reflux Time During the 4-hour Post-dosing Period (i.e. the Longest Period With pH Below pH 4)

    The longest reflux time during the 4-hour post-dosing period (i.e. the longest period with pH below pH 4) for Compound Sodium Alginate Double Action Chewable Tablets versus matching placebo tablets

    Time frame: 0 to 4 hours post-dose

  10. The DeMeester Scores During the 4-hour Post-dosing Period

    The DeMeester scores during the 4-hour post-dosing period for Compound Sodium Alginate Double Action Chewable Tablets versus matching placebo tablets. The DeMeester score is a composite score of the acid exposure during a prolonged ambulatory pH monitoring. The parameters that constitute the score are number of reflux episodes, number of episodes longer than 5 minutes, longest reflux duration, total percentage of monitoring time with pH below 4, and the percentage of time with pH below 4 in an upright position and supine position, respectively. The DeMeester score is the sum of the scores calculated for each of the 6 parameters. A score more than 14.7 is considered abnormal acid reflux, scores between 14.7 and 100 are regarded as mild-to-moderate GERD, and a score greater than 100 is regarded as severe GERD.

    Time frame: 0 to 4 hours post-dose

07

Results

Posted Apr 29, 2025

Participant flow

Participant flow — Overall Study
MilestoneGroup AGroup B
Started2223
Completed2123
Not completed10
Withdrew: Withdrawal by subject10

Outcome measures

PrimaryPercentage of Time During the 4-hour Post-dosing Period With pH Below pH 4

The primary efficacy endpoint will be the percentage of time during the 4-hour post-dosing period with pH below pH 4 for Compound Sodium Alginate Double Action Chewable Tablets versus matching placebo tablets

Time frame:
0 to 4 hours post-dose
Reported as:
Least squares mean · percentage of time with pH below pH 4
Percentage of Time During the 4-hour Post-dosing Period With pH Below pH 4
percentage of time with pH below pH 4Sodium Alginate Double Action Chewable TabletsPlacebo Tablets
Percentage of Time During the 4-hour Post-dosing Period With pH Below pH 45.14 (-0.27 to 10.56)14.94 (9.52 to 20.35)
Statistical analysis
  • Sodium Alginate Double Action Chewable Tablets vs Placebo Tablets · Mixed Models Analysis · p = 0.0003 · Mean difference (final values): -9.79 · 95% CI -14.85 to -4.74
SecondaryPercentage of Time During the 4-hour Post-dosing Period With pH Below pH 5

Percentage of time during the 4-hour post-dosing period with pH below pH 5 for Compound Sodium Alginate Double Action Chewable Tablets versus matching placebo tablets

Time frame:
0 to 4 hours post-dose
Reported as:
Least squares mean · percentage of time with pH below pH 5
Percentage of Time During the 4-hour Post-dosing Period With pH Below pH 5
percentage of time with pH below pH 5Sodium Alginate Double Action Chewable TabletsPlacebo Tablets
Percentage of Time During the 4-hour Post-dosing Period With pH Below pH 510.40 (3.40 to 17.40)26.16 (19.16 to 33.16)
Statistical analysis
  • Sodium Alginate Double Action Chewable Tablets vs Placebo Tablets · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): -15.76 · 95% CI -22.82 to -8.71
SecondaryNumber of Occasions During the 4-hour Post-dosing Period When pH Falls Below pH 4

Number of occasions during the 4-hour post-dosing period when pH falls below pH 4 for Compound Sodium Alginate Double Action Chewable Tablets versus matching placebo tablets

Time frame:
0 to 4 hours post-dose
Reported as:
Least squares mean · Number of occasions pH fell below 4
Number of Occasions During the 4-hour Post-dosing Period When pH Falls Below pH 4
Number of occasions pH fell below 4Sodium Alginate Double Action Chewable TabletsPlacebo Tablets
Number of Occasions During the 4-hour Post-dosing Period When pH Falls Below pH 411.5 (3.4 to 19.6)30.9 (22.8 to 39.1)
Statistical analysis
  • Sodium Alginate Double Action Chewable Tablets vs Placebo Tablets · Mixed Models Analysis · p = 0.0004 · Median difference (final values): -19.4 · 95% CI -29.6 to -9.2
SecondaryNumber of Occasions During the 4-hour Post-dosing Period When pH Falls Below pH 5

Number of occasions during the 4-hour post-dosing period when pH falls below pH 5 for Compound Sodium Alginate Double Action Chewable Tablets versus matching placebo tablets

Time frame:
0 to 4 hours post-dose
Reported as:
Least squares mean · Number of occasions pH fell below 5
Number of Occasions During the 4-hour Post-dosing Period When pH Falls Below pH 5
Number of occasions pH fell below 5Sodium Alginate Double Action Chewable TabletsPlacebo Tablets
Number of Occasions During the 4-hour Post-dosing Period When pH Falls Below pH 517.3 (9.5 to 25.1)33.6 (25.8 to 41.4)
Statistical analysis
  • Sodium Alginate Double Action Chewable Tablets vs Placebo Tablets · Mixed Models Analysis · p = 0.0019 · Mean difference (final values): -16.3 · 95% CI -26.2 to -6.4
SecondaryNumber of Reflux Episodes During the 4-hour Post-dosing Period With pH Below pH 4 for at Least 5 Minutes

Number of reflux episodes during the 4-hour post-dosing period with pH below pH 4 for at least 5 minutes for Compound Sodium Alginate Double Action Chewable Tablets versus matching placebo tablets

Time frame:
0 to 4 hours post-dose
Reported as:
Least squares mean · Number of reflux episodes
Number of Reflux Episodes During the 4-hour Post-dosing Period With pH Below pH 4 for at Least 5 Minutes
Number of reflux episodesSodium Alginate Double Action Chewable TabletsPlacebo Tablets
Number of Reflux Episodes During the 4-hour Post-dosing Period With pH Below pH 4 for at Least 5 Minutes0.6 (-0.1 to 1.3)1.4 (0.7 to 2.1)
Statistical analysis
  • Sodium Alginate Double Action Chewable Tablets vs Placebo Tablets · Mixed Models Analysis · p = 0.0290 · Mean difference (final values): -0.8 · 95% CI -1.6 to -0.1
SecondaryPercentage of Time During the First Hour Post-dosing With pH Below pH 4

Percentage of time during the first hour post-dosing with pH below pH 4 for Compound Sodium Alginate Double Action Chewable Tablets versus matching placebo tablets

Time frame:
0 to 1 hour post-dose
Reported as:
Least squares mean · percentage of time with pH below pH 4
Percentage of Time During the First Hour Post-dosing With pH Below pH 4
percentage of time with pH below pH 4Sodium Alginate Double Action Chewable TabletsPlacebo Tablets
Percentage of Time During the First Hour Post-dosing With pH Below pH 42.00 (-3.43 to 7.44)16.41 (10.98 to 21.84)
Statistical analysis
  • Sodium Alginate Double Action Chewable Tablets vs Placebo Tablets · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): -14.40 · 95% CI -20.57 to -8.23
SecondaryPercentage of Time During the First Hour Post-dosing With pH Below pH 5

Percentage of time during the first hour post-dosing with pH below pH 5 for Compound Sodium Alginate Double Action Chewable Tablets versus matching placebo tablets

Time frame:
0 to 1 hour post-dose
Reported as:
Least squares mean · percentage of time with pH below pH 5
Percentage of Time During the First Hour Post-dosing With pH Below pH 5
percentage of time with pH below pH 5Sodium Alginate Double Action Chewable TabletsPlacebo Tablets
Percentage of Time During the First Hour Post-dosing With pH Below pH 54.23 (-2.82 to 11.29)27.60 (20.55 to 34.65)
Statistical analysis
  • Sodium Alginate Double Action Chewable Tablets vs Placebo Tablets · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): -23.37 · 95% CI -31.55 to -15.19
SecondaryNumber of Occasions During the First Hour Post-dosing When pH Falls Below pH 4

Number of occasions during the first hour post-dosing when pH falls below pH 4 for Compound Sodium Alginate Double Action Chewable Tablets versus matching placebo tablets

Time frame:
0 to 1 hour post-dose
Reported as:
Least squares mean · Number of occasions pH fell below 4
Number of Occasions During the First Hour Post-dosing When pH Falls Below pH 4
Number of occasions pH fell below 4Sodium Alginate Double Action Chewable TabletsPlacebo Tablets
Number of Occasions During the First Hour Post-dosing When pH Falls Below pH 41.7 (-0.6 to 4.0)9.1 (6.7 to 11.4)
Statistical analysis
  • Sodium Alginate Double Action Chewable Tablets vs Placebo Tablets · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): -7.3 · 95% CI -10.0 to -4.6
SecondaryNumber of Occasions During the First Hour Post-dosing When pH Falls Below pH 5

Number of occasions during the first hour post-dosing when pH falls below pH 5 for Compound Sodium Alginate Double Action Chewable Tablets versus matching placebo tablets

Time frame:
0 to 1 hour post-dose
Reported as:
Least squares mean · Number of occasions pH fell below 5
Number of Occasions During the First Hour Post-dosing When pH Falls Below pH 5
Number of occasions pH fell below 5Sodium Alginate Double Action Chewable TabletsPlacebo Tablets
Number of Occasions During the First Hour Post-dosing When pH Falls Below pH 53.1 (0.8 to 5.4)9.5 (7.2 to 11.8)
Statistical analysis
  • Sodium Alginate Double Action Chewable Tablets vs Placebo Tablets · Mixed Models Analysis · p = 0.0001 · Mean difference (final values): -6.4 · 95% CI -9.4 to -3.3
SecondaryThe Longest Reflux Time During the 4-hour Post-dosing Period (i.e. the Longest Period With pH Below pH 4)

The longest reflux time during the 4-hour post-dosing period (i.e. the longest period with pH below pH 4) for Compound Sodium Alginate Double Action Chewable Tablets versus matching placebo tablets

Time frame:
0 to 4 hours post-dose
Reported as:
Least squares mean · minutes
The Longest Reflux Time During the 4-hour Post-dosing Period (i.e. the Longest Period With pH Below pH 4)
minutesSodium Alginate Double Action Chewable TabletsPlacebo Tablets
The Longest Reflux Time During the 4-hour Post-dosing Period (i.e. the Longest Period With pH Below pH 4)3.3 (-1.3 to 7.9)9.6 (5.1 to 14.2)
Statistical analysis
  • Sodium Alginate Double Action Chewable Tablets vs Placebo Tablets · Mixed Models Analysis · p = 0.0075 · Mean difference (final values): -6.3 · 95% CI -10.9 to -1.8
SecondaryThe DeMeester Scores During the 4-hour Post-dosing Period

The DeMeester scores during the 4-hour post-dosing period for Compound Sodium Alginate Double Action Chewable Tablets versus matching placebo tablets. The DeMeester score is a composite score of the acid exposure during a prolonged ambulatory pH monitoring. The parameters that constitute the score are number of reflux episodes, number of episodes longer than 5 minutes, longest reflux duration, total percentage of monitoring time with pH below 4, and the percentage of time with pH below 4 in an upright position and supine position, respectively. The DeMeester score is the sum of the scores calculated for each of the 6 parameters. A score more than 14.7 is considered abnormal acid reflux, scores between 14.7 and 100 are regarded as mild-to-moderate GERD, and a score greater than 100 is regarded as severe GERD.

Time frame:
0 to 4 hours post-dose
Reported as:
Least squares mean · score on a scale
The DeMeester Scores During the 4-hour Post-dosing Period
score on a scaleSodium Alginate Double Action Chewable TabletsPlacebo Tablets
The DeMeester Scores During the 4-hour Post-dosing Period14.842 (2.125 to 27.560)38.987 (26.270 to 51.704)
Statistical analysis
  • Sodium Alginate Double Action Chewable Tablets vs Placebo Tablets · Mixed Models Analysis · p = 0.0007 · Mean difference (final values): -24.145 · 95% CI -37.432 to -10.858

Adverse events

Collected over Up to 19 days, from the time informed consent was provided until the Day 7 (+/- 2 days) visit. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group A0/22 (0%)0/22 (0%)0/22 (0%)
Group B0/23 (0%)0/23 (0%)2/23 (8.7%)
Most frequent other events
Most frequent other events
EventGroup AGroup B
White blood cell count decreasedInvestigations0/222/23

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Group AGroup BTotal
<=18 years000
Between 18 and 65 years212344
>=65 years101
Age, Continuous
Age, Continuous(years)Group AGroup BTotal
Mean41.6 ± 15.2739.3 ± 16.9040.4 ± 15.98
Sex: Female, Male
Sex: Female, Male(Participants)Group AGroup BTotal
Female11819
Male111526
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Group AGroup BTotal
Caucasian000
Asian222345
Afro-Caribbean000
Other000
Region of Enrollment
Region of Enrollment(participants)Group AGroup BTotal
China222345
08

Study locations

1 site
  • RB Investigational Sites
    Shanghai, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2013 to primary completion in Dec 2013, 5 months.

Results were first posted in Apr 2025, 11 years 4 months after primary completion.

Of 20 phase 3 interventional studies under Gastroesophageal Reflux, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 49. This study's 5 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 31, 2013
First posted
Jun 7, 2013
StartActual
Jul 2, 2013
Primary completionActual
Dec 2013
CompletionActual
Dec 2013
Results first posted
Apr 29, 2025
Last update
Apr 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01872897
Lead sponsor
Reckitt Benckiser Healthcare (UK) Limited
Responsible party
Sponsor
First posted
Jun 7, 2013
Start date
Jul 2, 2013
Primary completion
Dec 2013
Completion
Dec 2013
Results posted
Apr 29, 2025
Last update
Apr 29, 2025

Study contacts

Yuan Yaozong, MD, PhD
principal investigator · Shanghai Jiao Tong University, School of Medicine, Shanghai, China

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Gastroesophageal Reflux →

Other studies from this sponsor

Reckitt Benckiser Healthcare (UK) Limited →

Start the discussion